AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00962416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent (Gazelle)
Description: A bare-metal stent of identical design without surface application of polymer and drug.
Study NCT03042663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: USG stellate ganglion block
Description: After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
Study NCT03951259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo pills are made identical to the investigating SM934 in appearance.
Study NCT02168816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Antibacterial Agent
Description: Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
Study NCT02168816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antibacterial Agent
Description: Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
Study NCT03717727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: 16-week home-based exercise intervention with exergaming system and usual treatment.
Study NCT03717727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 16-week home-based exercise by standard protocol and usual treatment.
Study NCT03140033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Tablet
Description: at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
Study NCT03140033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranitidine Oral Tablet
Description: at cord clamping the patient will recieve ranitidine sublingually
Study NCT01100203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
Study NCT02365272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Amikacin administered in a single dose for critical care patients
Study NCT01730625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for anxiety
Study NCT03383848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Management Software
Description: The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days.
Study NCT01728298 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SLITone ULTRA HDM immunotherapy
Study NCT03365232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non custom base attachment
Description: non custom base attachment
Study NCT01730625 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy for anxiety
Study NCT01730625 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy for anxiety
Study NCT01730625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment
Study NCT01252992 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis
Description: 1. identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~2. Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction.
Study NCT01252992 — intervention group
Intervention type: RADIATION
Intervention: Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM
Description: at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
Study NCT01252992 — intervention group
Intervention type: OTHER
Intervention: Immunologic analysis
Description: For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
Study NCT01252992 — intervention group
Intervention type: OTHER
Intervention: QuantiferonTB Gold test
Description: at M0, M2, M6 and in case of PR+.
Study NCT03365232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: custom base attachment
Description: custom base attachment
Study NCT02433444 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: ERCP's performed at Cedars-Sinai Medical Center.
Study NCT01156454 — intervention group
Intervention type: PROCEDURE
Intervention: X-ray
Description: surgical specimen taken to radiology and contents x-rayed
Study NCT01562184 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS device
Description: Sham tDCS
Study NCT01562184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix tDCS device
Description: Active tDCS
Study NCT00667732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
Study NCT00667732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5mcg twice a day, increased to 10mcg twice a day for 24 weeks
Study NCT01522014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head
Study NCT01522014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head
Study NCT02123940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung ultrasound score
Description: Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
Study NCT02123940 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lung ultrasound score
Description: Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
Study NCT03890484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Type - New Peer
Description: Participants drink with 2 unfamiliar confederate peers
Study NCT03890484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Type - Close Friends
Description: Participants drink with 2 close friends
Study NCT01314066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
Study NCT01314066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
Study NCT04012905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids for Systemic Use
Description: Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month
Study NCT01930669 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gravitational sympathetic stimulus
Description: Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique.
Study NCT00672139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Study NCT00135408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab+ Placebo
Description: Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
Study NCT00135408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab+ Budesonide
Description: Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
Study NCT01089933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block (TPVB)
Description: The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
Study NCT01089933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic
Description: At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
Study NCT00278486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation.
Description: Autologous hematopoietic stem cell transplantation will be performed.
Study NCT03233308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic Solution 0.02%
Description: 1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
Study NCT03233308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Netarsudil Ophthalmic Solution 0.02%
Description: 1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
Study NCT03233308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: 1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
Study NCT03233308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
Study NCT04605068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse preputial island flap (Duckett's technique)
Study NCT04605068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-faced preputial flap (DFPF)
Study NCT04002206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
Study NCT04002206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretch
Description: Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
Study NCT01240772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: doppler-guided arterial ligation with mucopexy
Description: doppler-guided arterial ligation with mucopexy
Study NCT01240772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stapled haemorrhoidopexy according to Longo
Description: stapled haemorrhoidopexy according to Longo
Study NCT03698214 — intervention group
Intervention type: OTHER
Intervention: reversed shock index < 1
Description: Among patients with isolated TBI, those with an RSI \< 1 had higher mortality
Study NCT03698214 — intervention group
Intervention type: OTHER
Intervention: reversed shock index ≥ 1
Description: Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
Study NCT03224832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artery-first Approach
Description: Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~* The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas.
Study NCT03224832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Approach
Description: In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
Study NCT00498706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive behavioral therapy (T-CBT)
Description: Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
Study NCT04012905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids for Systemic Use
Description: Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month
Study NCT00518206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 ISCOMATRIX® vaccine
Description: NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Study NCT00518206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Study NCT03075878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered via IV infusion.
Study NCT03480815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal Temperature Controlled Laminar Flow Device
Description: Record of the time to first asthma exacerbation, lung function and exhaled NO level
Study NCT03480815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: None Device
Description: Record of the time to first asthma exacerbation, lung function and exhaled NO level
Study NCT05643222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: red tint contact lenses
Description: to compare the performance of these lenses.
Study NCT04520256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training for Dysregulated Eating
Description: Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
Study NCT02477735 — intervention group
Intervention type: DEVICE
Intervention: Actigraphy
Description: Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
Study NCT03454269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
Study NCT00498706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face administered CBT (FtF-CBT)
Description: Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
Study NCT00794989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ground Flaxseed
Description: Given orally
Study NCT00794989 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Participants randomized to Arm 2 do not receive any intervention
Study NCT02889679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater resection
Description: Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
Study NCT02889679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional (gas distended colon) resection
Description: Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.